NCT00881426已完成1 期
Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study of Sandoz GmbH and Bristol-Myers Squibb (Cefzil) 500 mg Cefprozil Tablets In Healthy Adults Volunteers Under Fasting Conditions
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Sandoz
- 入组人数
- 26
- 主要终点
- Bioequivalence based on AUC and Cmax
研究概览
简要总结
To demonstrate the relative bioavailability of Cefzil 500 mg Cefprozil tablets under fasting conditions.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 54 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.
排除标准
- •Positive test results for HIV or hepatitis B or C.
- •Treatment for drug or alcohol dependence.
研究组 & 干预措施
1
Experimental
Cefprozil 500 mg Tablets (Sandoz GmbH)
干预措施: Cefprozil 500 mg Tablets (Sandoz GmbH) (Drug)
2
Active Comparator
Cefzil (Cefprozil) 500 mg Tablets (Bristol-Myers Squibb)
干预措施: Cefzil (Cefprozil) 500 mg Tablets (Bristol-Myers Squibb) (Drug)
结局指标
主要结局
Bioequivalence based on AUC and Cmax
时间窗: 16 days
次要结局
未报告次要终点
研究者
相似试验
已完成
1 期
To Demonstrate the Relative Bioavailability of Cefzil 500 mg Cefprozil Tablets Under Fed ConditionsHealthyNCT00881855Sandoz35
已完成
1 期
To Demonstrate the Relative Bioavailability of Cefzil 250 mg/5 ml Cefprozil Oral Suspension Fed ConditionsHealthyNCT00881400Sandoz24
已完成
1 期
To Demonstrate the Relative Bioavailability of Cefzil 250 mg/5 ml Cefprozil Oral Suspension Following a 10 ml Dose Fasting Conditions.HealthyNCT00881153Sandoz20
已完成
1 期
To Demonstrate the Relative Bioavailability of Cilostazol 50 mg Tablets Under Fasting ConditionsPainNCT00881231Sandoz26
已完成
1 期
Cefprozil 500 mg Tablets Under Fed ConditionsHealthyNCT00840866Teva Pharmaceuticals USA39